麻豆传媒

Drug is approved in combination with fludarabine

News, features, and commentary about cancer-related issues

Radiation exposure, type and cumulative dose of chemotherapy drive melanoma risk

Incidence of cytokine release syndrome was minimal with the investigational therapy

Also in TTHealthWatch: catheter material for PICC lines

News, features, and commentary about cancer-related issues

Phase III data show promising efficacy with manageable toxicity and feasible delivery

ORR of 80% at recommended dose of talquetamab, teclistamab but with high rates of grade 3/4 AEs

Study suggests that driver mutation monitoring could become standard practice, researcher says

Treatment tied to higher recovery odds and faster time to kidney recovery

FDA boxed warning led to multiple studies on the issue in 2024

News, features, and commentary about cancer-related issues

Studies show promising EFS, PFS, and OS at 3 to 8 years

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone